BACKGROUND: Primary treatment of endometrial cancer with progestogens is reserved for adjuvant or palliative treatment, although with unproven efficacy. CASE: We present a case of early endometrial cancer where a combination of oral progestogens and levonorgestrel releasing intrauterine system (Mirena) was used as a primary treatment, as the standard surgical treatment was deemed to carry an unacceptable mortality risk. CONCLUSION: Our treatment has resulted in reversion of the cancerous endometrial histological changes. This is encouraging, but obviously more cases and lengthier follow-up time are required in order to obtain more valid conclusions.
BACKGROUND: Primary treatment of endometrial cancer with progestogens is reserved for adjuvant or palliative treatment, although with unproven efficacy. CASE: We present a case of early endometrial cancer where a combination of oral progestogens and levonorgestrel releasing intrauterine system (Mirena) was used as a primary treatment, as the standard surgical treatment was deemed to carry an unacceptable mortality risk. CONCLUSION: Our treatment has resulted in reversion of the cancerous endometrial histological changes. This is encouraging, but obviously more cases and lengthier follow-up time are required in order to obtain more valid conclusions.
Authors: Andreas Obermair; Danny R Youlden; Joanne P Young; Noralane M Lindor; John A Baron; Polly Newcomb; Susan Parry; John L Hopper; Robert Haile; Mark A Jenkins Journal: Int J Cancer Date: 2010-12-01 Impact factor: 7.396
Authors: Navdeep Pal; Russell R Broaddus; Diana L Urbauer; Nyla Balakrishnan; Andrea Milbourne; Kathleen M Schmeler; Larissa A Meyer; Pamela T Soliman; Karen H Lu; Pedro T Ramirez; Lois Ramondetta; Diane C Bodurka; Shannon N Westin Journal: Obstet Gynecol Date: 2018-01 Impact factor: 7.661